Investing.com - Assertio Therapeutics (NASDAQ: ASRT) reported second quarter EPS of $0.0200, $0.04 better than the analyst estimate of $-0.0200. Revenue for the quarter came in at $30.7M versus the consensus estimate of $30.19M.
Guidance
Assertio Therapeutics sees FY 2024 revenue of $110.0000M-$125.0000M versus the analyst consensus of $120.6000M.
Assertio Therapeutics's stock price closed at $1.23. It is up 28.1300% in the last 3 months and down -61.4400% in the last 12 months.
Assertio Therapeutics saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Assertio Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Assertio Therapeutics's Financial Health score is "good performance".
Check out Assertio Therapeutics's recent earnings performance, and Assertio Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar